预约演示
AZ's Alexion inks $125M deal to resolve investor lawsuit over Soliris sales tactics
并购专利侵权IPO高管变更
Alexion's investors alleged that the company made false statements about its sales tactics for Soliris.
Alexionseven years have passed since Alexion’s then-CEO and CFO stepped down amid an investigation into improper sales practices. Now, the rare disease specialist can put the episode completely in the rearview mirror thanks to a settlement with investors.
Alexion, now part of AstraZeneca, has reached a $125 million deal with investors to resolve their class action lawsuit, the plaintiffs said in a court filing.
Alexionffs launched tAstraZenecan late 2016, a few weeks after Alexion disclosed an investigation into a whistleblower allegation about sales practices for the company’s flagship product, Soliris. The company’s then-CEO David Hallal and CFO Vika Sinha left the company shortly before the litigation kicked off.
Alexion’s stock price tumbled after the disclosure. Angry invesAlexionaimed that the company made false statements about its sales tactics, and that its share price was artificially inflated as a result.
Alexionbeginning of 2017, Alexion acknowledged that senior management pressured employees to convince customers to place their Soliris orders earlier than they would have otherwise.
The practice, known as “puAlexionales,” was intended to boost quarterly performance. Still, it wasn’t “inherently problematic or impermissible” as long as it didn’t violate U.S. accounting rules, the company said.
In the years after that episode, the company was dogged by government probes into its sales tactics. In 2019, Alexion, Jazz Pharma and Lundbeck together agreed to pay $122.6 million to resolve allegations that they illegally covered the copays for their products under Medicare.
And in 2020, Alexion paid $21.5 million to settle foreign corruption charges brought by the U.S. Securities anAlexionngJazz Pharman. ThLundbecky was said to have improperly paid Turkish and Russian government officials to win favorable treatment for Soliris. Alexion didn’t admit or deny the agency’s findings in that deal.
These days, Alexion’s focus has shifted to the company’s newAlexionnhibitor UltomiriAstraZenecarks to convert patients to the follow-on drug, Soliris’ sales dropped by 18% in the first half of the year to $1.6 billion. Ultomiris’ sales jumped 60% to $1.4 billion during the same period.
Meanwhile, bAlexionars to Soliris aren’t too far away. Through C5 inhibitorC5deal signedUltomiris Alexion will face Amgen’s Soliris biosimilar in the U.S. by 2025.Ultomiris
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
适应症
-靶点
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。